206198-07-4 Usage
Uses
Used in Bioluminiscent Probes:
Benzenemethanol, 3,5-difluoro-4-hydroxy(9CI) is used as a key component in the preparation of bioluminiscent probes with sulfatase activity. These probes are essential tools for studying human and prokaryotic cells, allowing researchers to gain insights into cellular processes and functions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Benzenemethanol, 3,5-difluoro-4-hydroxy(9CI) is utilized as an intermediate in the synthesis of various drugs and pharmaceutical compounds. Its unique chemical properties make it a valuable building block for the development of new medications with potential therapeutic applications.
Used in Chemical Research:
Benzenemethanol, 3,5-difluoro-4-hydroxy(9CI) is also employed in chemical research, where it serves as a starting material for the synthesis of various organic compounds. Its distinct structure and reactivity make it an attractive candidate for exploring new chemical reactions and developing novel synthetic pathways.
Used in Material Science:
In the field of material science, Benzenemethanol, 3,5-difluoro-4-hydroxy(9CI) may be used to develop new materials with specific properties, such as enhanced fluorescence or improved stability. Its unique molecular structure can contribute to the creation of advanced materials with potential applications in various industries, including electronics, optics, and biotechnology.
Check Digit Verification of cas no
The CAS Registry Mumber 206198-07-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,6,1,9 and 8 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 206198-07:
(8*2)+(7*0)+(6*6)+(5*1)+(4*9)+(3*8)+(2*0)+(1*7)=124
124 % 10 = 4
So 206198-07-4 is a valid CAS Registry Number.
206198-07-4Relevant academic research and scientific papers
GALACTOSIDE INHIBITOR OF GALECTINS
-
Page/Page column 95-96, (2020/05/21)
The present invention relates to a compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
